Argenx reports half year 2024 financial results and provides second quarter business update

$478 million in second quarter global net product sales first cidp patients treated with vyvgart ® hytrulo following june 21 st fda approval on track to begin four additional registrational studies across efgartigimod and empasiprubart by end of 2024 management to host conference call today at 2:30 pm cet (8:30 am et) regulated information – inside information july 25, 2024 7:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its half year 2024 results and provided a second quarter business update. “we were excited to unveil our ambition for the future of argenx – vision 2030 – last week, outlining our plan to develop and deliver continued and sustainable innovation for patients,” said tim van hauwermeiren, chief executive officer of argenx.
ARGX Ratings Summary
ARGX Quant Ranking